Short-term effect of topical brinzolamide on human central corneal thickness

European Journal of Ophthalmology

Volumn 18, Issue 3, 2008, Pages 338-340

  Örnek, Kemal ^a,b   Gullu R ^a   Ogurel T ^a   Ergin, A ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Brinzolamide; Central corneal thickness

Indexed keywords

BRINZOLAMIDE; DORZOLAMIDE; FLUOROMETHOLONE;

ADULT; AGED; ARTICLE; CAPSULOTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA THICKNESS; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LENS IMPLANTATION; MALE; NEODYMIUM LASER; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PHACOEMULSIFICATION; PRESSURE MEASUREMENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 54749155541     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800303     Document Type: Article

References (9)

1. Wang TH, Huang JY, Hung PT, Shieh JW, Chen YF. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. J Formos Med Assoc 2004; 103: 369-73.
2. Unal M, Yücel I, Akar Y. Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. J Cataract Refract Surg 2006; 32: 1499-502.
3. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998; 126: 400-8.
4. Almeida GC, Faria e Souza SJ. Effect of topical dorzolamide on rabbit central corneal thickness. Braz J Med Biol Res 2006; 39: 277-81.
5. Wirtitsch MG, Findl O, Kiss B, Petternel V, Heinzl H, Drexler W. Short-term effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. Arch Ophthalmol 2003; 121: 621-5.
6. Lass JH, Khosrof SA, Laurence JK, Horwitz B, Ghosh K, Adamsons I. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol 1998; 116: 1003-10.
7. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993; 111: 1343-50.
8. Wu KY, Wang HZ, Hong SJ. Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. Kaohsiung J Med Sci 2007; 23: 105-11.
9. Zhao JC, Chen T. Brinzolamide induced reversible corneal decompensation. Br J Ophthalmol 2005; 89: 389-90.